Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Iqbal, N."'
Autor:
Shehadeh N; Rambam Health Care Campus, Haifa, Israel.; Bar-Ilan University, Safed, Israel., Barrett T; University of Birmingham, Birmingham, United Kingdom., Galassetti P; AstraZeneca, Gaithersburg, MD., Karlsson C; AstraZeneca, Gothenburg, Sweden., Monyak J; AstraZeneca, Gaithersburg, MD., Iqbal N; AstraZeneca, Gaithersburg, MD., Tamborlane WV; Yale University, New Haven, CT.
Publikováno v:
NEJM evidence [NEJM Evid] 2023 Dec; Vol. 2 (12), pp. EVIDoa2300210. Date of Electronic Publication: 2023 Oct 04.
Autor:
Oulhaj A; Department of Epidemiology and Population Health, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates., Aziz F; Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Austria., Suliman A; Institute of Public Health, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates., Iqbal N; AstraZeneca Research and Development, Gaithersburg, Maryland, USA., Coleman RL; Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, UK., Holman RR; Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, UK., Sourij H; Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Austria.
Publikováno v:
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 May; Vol. 25 (5), pp. 1261-1270. Date of Electronic Publication: 2023 Feb 01.
Autor:
Iqbal N; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Electronic address: Nayyar.Iqbal@astrazeneca.com., Ambery P; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Logue J; Early-stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Mallappa A; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Sjöström CD; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Publikováno v:
Diabetes research and clinical practice [Diabetes Res Clin Pract] 2023 May; Vol. 199, pp. 110669. Date of Electronic Publication: 2023 Apr 17.
Autor:
Frías JP; National Research Institute, Los Angeles, California, USA., Maaske J; AstraZeneca, Gaithersburg, Maryland, USA., Suchower L; Kelly Services, Gaithersburg, Maryland, USA., Johansson L; Antaros Medical AB, BioVenture Hub, Mölndal, Sweden., Hockings PD; Antaros Medical AB, BioVenture Hub, Mölndal, Sweden.; MedTech West, Chalmers University of Technology, Gothenburg, Sweden., Iqbal N; AstraZeneca, Gaithersburg, Maryland, USA., Wilding JPH; Obesity and Endocrinology Research Group, Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Publikováno v:
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Jan; Vol. 24 (1), pp. 61-71. Date of Electronic Publication: 2021 Sep 28.
Autor:
Weissler EH; Division of Vascular Surgery, Duke University School of Medicine, Durham, NC, USA., Clare RM; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA., Lokhnygina Y; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA., Buse JB; Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC, USA., Goodman SG; Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.; Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada., Katona B; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Iqbal N; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Pagidipati NJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA., Sattar N; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK., Holman RR; Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK., Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA., Mentz RJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA., Patel MR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA., Jones WS; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
Publikováno v:
Diabetic medicine : a journal of the British Diabetic Association [Diabet Med] 2021 Oct; Vol. 38 (10), pp. e14552. Date of Electronic Publication: 2021 Mar 18.
Autor:
Wysham CH; Section of Endocrinology and Metabolism, MultiCare Rockwood Clinic, Spokane, Washington, USA cwysham@multicare.org., Rosenstock J; Dallas Diabetes Research Center at Medical City, Dallas, Texas, USA., Vetter ML; Bristol-Myers Squibb, Princeton, New Jersey, USA., Wang H; AstraZeneca, Gaithersburg, Maryland, USA., Hardy E; Late clinical development, AstraZeneca, Gaithersburg, Maryland, USA., Iqbal N; Clinical, Diabetes, Metabolism and GI, AstraZeneca, Gaithersburg, Maryland, USA.
Publikováno v:
BMJ open diabetes research & care [BMJ Open Diabetes Res Care] 2020 Oct; Vol. 8 (1).
Autor:
Bethel MA; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK (M.A.B., R.A.P., R.R.H.)., Stevens SR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.R.S., Y.L., R.J.M., A.F.H.)., Buse JB; Department of Medicine, University of North Carolina School of Medicine, Chapel Hill (J.B.B.)., Choi J; AstraZeneca Research and Development, Gaithersburg, MD (J.C., S.M.G., N.I., P.Ö.)., Gustavson SM; AstraZeneca Research and Development, Gaithersburg, MD (J.C., S.M.G., N.I., P.Ö.)., Iqbal N; AstraZeneca Research and Development, Gaithersburg, MD (J.C., S.M.G., N.I., P.Ö.)., Lokhnygina Y; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.R.S., Y.L., R.J.M., A.F.H.)., Mentz RJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.R.S., Y.L., R.J.M., A.F.H.)., Patel RA; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK (M.A.B., R.A.P., R.R.H.)., Öhman P; AstraZeneca Research and Development, Gaithersburg, MD (J.C., S.M.G., N.I., P.Ö.)., Schernthaner G; Department of Medicine, Rudolfstiftung Hospital-Vienna, Austria (G.S.)., Lecube A; University Hospital Arnau de Vilanova, Obesity, Diabetes and Metabolism Research Group (IRBLleida), Lleida, Spain (A.L.). Dr Bethel is now at Eli Lilly and Co., Indianapolis, IN. Dr Patel is now with the National Health Service, UK., Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.R.S., Y.L., R.J.M., A.F.H.)., Holman RR; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK (M.A.B., R.A.P., R.R.H.).
Publikováno v:
Circulation [Circulation] 2020 Apr 28; Vol. 141 (17), pp. 1360-1370. Date of Electronic Publication: 2020 Feb 26.
Autor:
Bethel MA; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, U.K., Mentz RJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Merrill P; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Buse JB; Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC., Chan JC; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong SAR, China., Goodman SG; St. Michael's Hospital, University of Toronto, Ontario, Canada.; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada., Iqbal N; AstraZeneca Research and Development, Gaithersburg, MD., Jakuboniene N; Department of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Katona B; AstraZeneca Research and Development, Gaithersburg, MD., Lokhnygina Y; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Lopes RD; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Maggioni AP; ANMCO Research Center, Florence, Italy., Ohman P; AstraZeneca Research and Development, Gaithersburg, MD., Tankova T; Clinical Center of Endocrinology, Medical University, Sofia, Bulgaria., Bakris GL; Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL., Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Holman RR; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, U.K. rury.holman@dtu.ox.ac.uk.
Publikováno v:
Diabetes care [Diabetes Care] 2020 Feb; Vol. 43 (2), pp. 446-452. Date of Electronic Publication: 2019 Nov 22.
Autor:
Badjatiya A; Department of Internal Medicine (A.B.), Duke University School of Medicine, Durham, NC., Merrill P; Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC., Buse JB; Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill (J.B.B.)., Goodman SG; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (S.G.G.).; St. Michael's Hospital, Department of Medicine, University of Toronto, ON, Canada (S.G.G.)., Katona B; AstraZeneca Research and Development, Gaithersburg, MD (B.K.)., Iqbal N, Pagidipati NJ; Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.; Division of Cardiology, Duke University School of Medicine, Durham, NC (N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.)., Sattar N; Institute of Cardiovascular and Medical Sciences, University of Glasgow (N.S.)., Holman RR; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, United Kingdom (R.R.H.)., Hernandez AF; Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.; Division of Cardiology, Duke University School of Medicine, Durham, NC (N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.)., Mentz RJ; Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.; Division of Cardiology, Duke University School of Medicine, Durham, NC (N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.)., Patel MR; Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.; Division of Cardiology, Duke University School of Medicine, Durham, NC (N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.)., Jones WS; Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.; Division of Cardiology, Duke University School of Medicine, Durham, NC (N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.).
Publikováno v:
Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2019 Dec; Vol. 12 (12), pp. e008018. Date of Electronic Publication: 2019 Nov 22.
Autor:
Fudim M; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (M.F., J.W., N.J.P., Y.L., R.D.L., A.F.H., R.J.M.)., White J; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (M.F., J.W., N.J.P., Y.L., R.D.L., A.F.H., R.J.M.)., Pagidipati NJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (M.F., J.W., N.J.P., Y.L., R.D.L., A.F.H., R.J.M.)., Lokhnygina Y; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (M.F., J.W., N.J.P., Y.L., R.D.L., A.F.H., R.J.M.)., Wainstein J; Diabetes Unit, The E. Wolfson Medical Center, Sackler Tel-Aviv University, Israel (J.W.)., Murin J; University Hospital, Bratislava, Slovakia (J.M.)., Iqbal N; AstraZeneca Research and Development, Gaithersburg, MD (N.I., P.Ö., B.R.)., Öhman P; AstraZeneca Research and Development, Gaithersburg, MD (N.I., P.Ö., B.R.)., Lopes RD; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (M.F., J.W., N.J.P., Y.L., R.D.L., A.F.H., R.J.M.)., Reicher B; AstraZeneca Research and Development, Gaithersburg, MD (N.I., P.Ö., B.R.)., Holman RR; Diabetes Trials Unit, University of Oxford, United Kingdom (R.R.H.)., Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (M.F., J.W., N.J.P., Y.L., R.D.L., A.F.H., R.J.M.)., Mentz RJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (M.F., J.W., N.J.P., Y.L., R.D.L., A.F.H., R.J.M.).
Publikováno v:
Circulation [Circulation] 2019 Nov 12; Vol. 140 (20), pp. 1613-1622. Date of Electronic Publication: 2019 Sep 23.